Xia, Tao
Li, Keyu
Niu, Nan
Shao, Yingkuan
Ding, Ding
Thomas, Dwayne L.
Jing, Hao
Fujiwara, Kenji
Hu, Haijie
Osipov, Arsen
Yuan, Chunhui
Wolfgang, Christopher L.
Thompson, Elizabeth D.
Anders, Robert A.
He, Jin
Mou, Yiping
Murphy, Adrian G.
Zheng, Lei http://orcid.org/0000-0003-4163-2541
Funding for this research was provided by:
National Institutes of Health (R01 CA169702, R01 CA197296, P50 CA062924, P30 CA006973)
Article History
Received: 13 January 2022
Accepted: 10 March 2022
First Online: 28 March 2022
Declarations
:
: It is Johns Hopkins Medical Institution-IRB approved.
: Not applicable.
: LZ receives grant support from Bristol-Meyer Squibb, Merck, Astrazeneca, iTeos, Amgen, NovaRock, Inxmed, and Halozyme. LZ is a paid consultant/Advisory Board Member at Biosion, Alphamab, NovaRock, Akrevia/Xilio, QED, Natera, Novagenesis, Ambrx, Snow Lake Capitals, and Mingruizhiyao. LZ holds shares at Alphamab and Mingruizhiyao. RAA receives grants from Bristol Myers Squibb and FLX Biologics. RAA is a paid consultant/Advisory Board Member at Bristol Myers Squibb, Merck SD, FLX Biologics, AstraZeneca, and Adaptive Biotech. All other authors declare no competing interests.